Physician profile
Sumant Rawat
NPI 1710930672
$4,731.97
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,485 · 2021: $1,539 · 2022: $419.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $552.53 | 2019-2022 | |
| Biogen, INC. | $359.32 | 2019-2022 | |
| Abbvie INC. | $237.15 | 2019-2022 | |
| Mdd US Operations, LLC | $228.85 | 2019-2022 | |
| Allergan, INC. | $228.10 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $220.06 | 2019-2020 | |
| Genzyme Corporation | $217.34 | 2019-2022 | |
| Acorda Therapeutics, INC | $173.45 | 2019-2022 | |
| Ucb, INC. | $161.38 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $157.70 | 2019-2021 | |
| Amgen INC. | $152.93 | 2019-2021 | |
| Emd Serono, INC. | $150.13 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $142.65 | 2019-2021 | |
| Tanabe Pharma America, INC. | $140.03 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $115.04 | 2019-2021 |
Show all 42 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumant Rawat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.